165 related articles for article (PubMed ID: 32665093)
21. The impact of dermatological toxicities of anti-cancer therapy on the dermatological quality of life of cancer patients.
Ra HS; Shin SJ; Kim JH; Lim H; Cho BC; Roh MR
J Eur Acad Dermatol Venereol; 2013 Jan; 27(1):e53-9. PubMed ID: 22329482
[TBL] [Abstract][Full Text] [Related]
22. Acneiform eruptions with combination targeted cancer therapy in colorectal cancer patients.
Ibraheim MK; Lo J; Gupta R; Parseghian C; Patel AB
Support Care Cancer; 2022 Oct; 30(10):8051-8058. PubMed ID: 35771289
[TBL] [Abstract][Full Text] [Related]
23. Effects of Colloidal Oatmeal Lotion on Symptoms of Dermatologic Toxicities Induced by Epidermal Growth Factor Receptor Inhibitors.
Ke YT; Kuo CC
Adv Skin Wound Care; 2017 Jan; 30(1):27-34. PubMed ID: 27984271
[TBL] [Abstract][Full Text] [Related]
24. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group.
Lacouture ME; Maitland ML; Segaert S; Setser A; Baran R; Fox LP; Epstein JB; Barasch A; Einhorn L; Wagner L; West DP; Rapoport BL; Kris MG; Basch E; Eaby B; Kurtin S; Olsen EA; Chen A; Dancey JE; Trotti A
Support Care Cancer; 2010 Apr; 18(4):509-22. PubMed ID: 20145956
[TBL] [Abstract][Full Text] [Related]
25. Clinical management of EGFRI dermatologic toxicities: US perspective.
Lacouture ME; Cotliar J; Mitchell EP
Oncology (Williston Park); 2007 Oct; 21(11 Suppl 5):17-21. PubMed ID: 18154214
[TBL] [Abstract][Full Text] [Related]
26. Cutaneous side-effects in patients on long-term treatment with epidermal growth factor receptor inhibitors.
Osio A; Mateus C; Soria JC; Massard C; Malka D; Boige V; Besse B; Robert C
Br J Dermatol; 2009 Sep; 161(3):515-21. PubMed ID: 19466958
[TBL] [Abstract][Full Text] [Related]
27. Managing skin toxicities related to panitumumab.
Bergman H; Walton T; Del Bel R; Seki JT; Rafii A; Xu W; Koren G; Shear N; Krzyzanowska MK; Howell D; Liu G
J Am Acad Dermatol; 2014 Oct; 71(4):754-9. PubMed ID: 25085331
[TBL] [Abstract][Full Text] [Related]
28. An Analysis of Risk Factors for the Development of Acneiform Eruptions in Patients on Monoclonal Antibody Epidermal Growth Factor Receptor Inhibitors.
Bierbrier R; D'Aguanno K; Oliel S; Zeng Y; Esfahani K; Pehr K
J Cutan Med Surg; 2023 Nov; 27(6):614-620. PubMed ID: 37942582
[TBL] [Abstract][Full Text] [Related]
29. The Most Common Cutaneous Side Effects of Epidermal Growth Factor Receptor Inhibitors and Their Management.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2015; 23(4):282-8. PubMed ID: 26724881
[TBL] [Abstract][Full Text] [Related]
30. A prospective crossover pilot study to evaluate the use of a topical wound gel in patients with cutaneous toxicity caused by epidermal growth factor receptor inhibitors.
Wong SF; Lindgren A; Mummaneni M; Byun T; Vasko C; Arenos R; Alexson E; Osann K
J Support Oncol; 2010; 8(5):202-8. PubMed ID: 21086877
[TBL] [Abstract][Full Text] [Related]
31. The Effects of Association of Topical Polydatin Improves the Preemptive Systemic Treatment on EGFR Inhibitors Cutaneous Adverse Reactions.
Bavetta M; Silvaggio D; Campione E; Sollena P; Formica V; Coletta D; Graziani G; Romano MCP; Roselli M; Peris K; Bianchi L
J Clin Med; 2021 Jan; 10(3):. PubMed ID: 33530427
[TBL] [Abstract][Full Text] [Related]
32. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer.
Eng C
Nat Rev Clin Oncol; 2009 Apr; 6(4):207-18. PubMed ID: 19333227
[TBL] [Abstract][Full Text] [Related]
33. Retrospective Analysis of Skin Toxicity in Patients under Anti-EGFR Tyrosine Kinase Inhibitors: Our Experience in Lung Cancer.
Annunziata MC; Ferrillo M; Cinelli E; Panariello L; Rocco D; Fabbrocini G
Open Access Maced J Med Sci; 2019 Mar; 7(6):973-977. PubMed ID: 30976343
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy and biologic use in the routine management of metastatic colorectal cancer in Australia: is clinical practice following the evidence?
Semira C; Wong HL; Field K; Lee M; Lee B; Nott L; Shapiro J; Wong R; Tie J; Tran B; Richardson G; Zimet A; Lipton L; Tamjid B; Burge M; Ma B; Johns J; Harold M; Gibbs P
Intern Med J; 2019 Apr; 49(4):446-454. PubMed ID: 30230679
[TBL] [Abstract][Full Text] [Related]
35. A prospective study to validate the functional assessment of cancer therapy (FACT) for epidermal growth factor receptor inhibitor (EGFRI)-induced dermatologic toxicities FACT-EGFRI 18 questionnaire: SWOG S1013.
Wong SF; Unger JM; Wade JL; Wagner LI; Lacouture ME; Humphries KC; Moseley A; Arnold K; Velasco MR; Floyd JD; Esparaz BT; Barzi A; Lenz HJ; Koczywas M; Dakhil S; Burton GV; Fisch MJ; Henry NL; Hershman DL; Moinpour CM
J Patient Rep Outcomes; 2020 Jul; 4(1):54. PubMed ID: 32642992
[TBL] [Abstract][Full Text] [Related]
36. Topical doxycycline foam 4% for prophylactic management of epidermal growth factor receptor inhibitor skin toxicity: an exploratory phase 2, randomized, double-blind clinical study.
Shacham Shmueli E; Geva R; Yarom N; Hubert A; Keynan R; Kedem TH; Eini M; Tamarkin D; Shirvan M
Support Care Cancer; 2019 Aug; 27(8):3027-3033. PubMed ID: 30607677
[TBL] [Abstract][Full Text] [Related]
37. Translation and linguistic validation of the FACT-EGFRI-18 quality of life instrument from English into Dutch.
Boers-Doets CB; Gelderblom H; Lacouture ME; Bredle JM; Epstein JB; Schrama NA; Gall H; Ouwerkerk J; Brakenhoff JA; Nortier JW; Kaptein AA
Eur J Oncol Nurs; 2013 Dec; 17(6):802-7. PubMed ID: 23571183
[TBL] [Abstract][Full Text] [Related]
38. Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial.
Saint-Jean A; Reguart N; Eixarch A; Adán A; Castellà C; Sánchez-Dalmau B; Sainz-de-la-Maza M
J Fr Ophtalmol; 2018 Dec; 41(10):955-962. PubMed ID: 30473235
[TBL] [Abstract][Full Text] [Related]
39. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
Lynch TJ; Kim ES; Eaby B; Garey J; West DP; Lacouture ME
Oncologist; 2007 May; 12(5):610-21. PubMed ID: 17522250
[TBL] [Abstract][Full Text] [Related]
40. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M; Sibaud V
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
